TY - JOUR T1 - Drug-induced eosinophilic pleural effusion JF - European Respiratory Review JO - EUROPEAN RESPIRATORY REVIEW SP - 300 LP - 301 DO - 10.1183/09059180.00005811 VL - 20 IS - 122 AU - R. Krenke AU - R.W. Light Y1 - 2011/12/01 UR - http://err.ersjournals.com/content/20/122/300.abstract N2 - To the Editors:We read with great interest the article by Alagha et al. [1] in the June issue of the European Respiratory Review. Since, in our opinion, eosinophilic pleural effusion (EPE), and drug-induced EPE in particular, is an interesting issue, we would like to add some comments to this article.It should be realised that our knowledge on drug-induced EPE comes almost exclusively from case reports. Although none of the larger series presenting the aetiology of EPE reported the true incidence of drug-induced EPE, the percentage of patients with drug-induced EPE seems to be low. Nevertheless, as in the majority of these patients drug discontinuation is sufficient for resolution of pleural effusion, pharmacological agents should always be considered as a potential cause of pleural effusion, particularly in EPE.Although numerous drugs can induce pleuritis and pleural effusion, the list of agents associated with eosinophilic pleuritis is not extensive [2–4]. Some drugs used in psychiatry and neurology are some of the most important, including valproic acid (and its derivatives) and dantrolene [5–8]. EPE was also reported as a complication of treatment with tazinidine, trimipramine and fluoxetine [9–11]. It is interesting that, in a substantial number of reports on … ER -